Powder: -20°C for 3 years | In solvent: -80°C for 1 year
APX-115 free base (Ewha-18278 free base) (Ewha-18278 free base) is a potent, orally active pan NADPH oxidase (Nox) inhibitor (Kis: 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2, and Nox4). APX-115 effectively prevents kidney injury.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 12,000 | |||
5 mg | 在庫あり | ¥ 28,000 | |||
10 mg | 在庫あり | ¥ 45,500 | |||
25 mg | 在庫あり | ¥ 91,500 | |||
50 mg | 在庫あり | ¥ 136,500 | |||
100 mg | 在庫あり | ¥ 199,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 29,000 |
説明 | APX-115 free base (Ewha-18278 free base) (Ewha-18278 free base) is a potent, orally active pan NADPH oxidase (Nox) inhibitor (Kis: 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2, and Nox4). APX-115 effectively prevents kidney injury. |
ターゲット&IC50 | NOX2:0.57 μM (ki), Nox4:0.63 μM (ki), NOX1:ki:1.08 μM |
In vitro | In the mouse podocyte cell line, APX-115 free base (5?μM; 60?min) almost completely suppresses high glucose-induced proinflammatory and profibrotic molecule expression. In the kidney, APX-115 free base attenuates Nox gene upregulation and protein expression while improving inflammatory and fibrotic processes [2]. |
In vivo | APX-115 free base treatment decreases the urinary excretion of albumin and plasma creatinine levels. APX-115 (oral gavage; 60?mg/kg/day; for 12 weeks) significantly improves insulin resistance in diabetic mice. |
別名 | Ewha-18278 free base |
分子量 | 279.34 |
分子式 | C17H17N3O |
CAS No. | 1270084-92-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 245 mg/mL (877.07 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
APX-115 free base 1270084-92-8 Immunology/Inflammation Metabolism NADPH-oxidase NADPH plasma APX 115 free base NOX Inhibitor injury Nox1 kidney Ewha18278 albumin Ewha 18278 APX115 free base Ewha-18278 insulin APX115 Nox3 resistance APX-115 NADPH Oxidase inhibit Ewha-18278 free base APX 115 creatinine Nox2 inhibitor